Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1999
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue repair. Key products include ORTHOVISC (human osteoarthritis, marketed internationally; investigational in U.S.), HYVISC (equine osteoarthritis), and AMVISC/AMVISC Plus (ophthalmic surgery, manufactured for Bausch & Lomb). The company is also developing INCERT (adhesion prevention) and Ossigel (bone fracture healing).
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Net Sales | $3,224,578 | $2,754,419 |
| Gross Profit | $1,516,407 | $1,410,947 |
| Gross Margin | 47.0% | 51.2% |
| Operating Income | $53,599 | $371,982 |
| Net Income | $344,749 | $637,006 |
| Diluted EPS | $0.03 | $0.06 |
| Cash & Equivalents (End of Period) | $5,608,453 | $22,363,689 |
| Short-term Investments | $16,085,569 | N/A |
| Total Liquid Assets | $21,694,022 | $22,363,689 |
| Working Capital | $25,315,708 | N/A |
| Accumulated Deficit | $(1,335,664) | $(1,680,412) |
Cash Flow Summary (Q1 1999):
- Net cash provided by operating activities: $1,338,772
- Net cash used in investing activities: $(4,532,242) (primarily short-term investments and equipment)
- Net cash used in financing activities: $(1,910,596) (stock repurchases)
- Net decrease in cash: $(5,104,067)
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17.1% ($470k) driven by a 104% increase in ORTHOVISC sales.
- Margin Compression: Gross margin declined 4.2% due to scale-up costs associated with expanding manufacturing capacity.
- Expense Increases:
- Research & Development (R&D) rose 41% ($205k) primarily due to ORTHOVISC clinical trial costs.
- Selling, General & Administrative (SG&A) rose 41% ($219k) due to marketing costs, staffing, and stock compensation amortization.
- Profitability: Net income decreased 46% to $345k, despite revenue growth, due to higher operating expenses and lower gross margins.
- Liquidity: Cash and cash equivalents decreased by $5.1 million, largely due to stock repurchases ($1.9 million) and increased short-term investments ($4.1 million).
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Manufacturing: The company spent $396k in Q1 on capacity expansion and expects to spend an additional $1.6 million in 1999. Capacity is projected to meet demand through 2003.
- Clinical Trials: An estimated $2.5 million expenditure is expected in 1999 for the ORTHOVISC Phase III clinical trial, which commenced in late April 1999 following FDA approval of an Investigational Device Exemption (IDE).
- Capital Resources: Management believes current cash ($21.7 million in liquid assets) is sufficient for at least 24 months, though future financing may be required for new facilities or if sales do not meet expectations.
- Stock Repurchase: The company repurchased 394,800 shares in Q1 1999. Total repurchases since the plan's inception reached 762,100 shares at an average cost of $5.08.
Key Risks & Contingencies:
- Regulatory Approval: ORTHOVISC is a Class III device requiring FDA Pre-Market Approval (PMA). The initial PMA was rejected in 1998; success depends on the new clinical trial. Failure to obtain approval by Jan 1, 2001, could allow partner Zimmer to terminate the distribution agreement.
- Customer Concentration: Bausch & Lomb Surgical accounted for 68% of product revenue in Q1 1999. A single customer accounted for 25% of ORTHOVISC revenue.
- Profitability Uncertainty: Despite Q1 profitability, the company has an accumulated deficit of $1.3 million and no assurance of sustained future profits.
- Year 2000 Compliance: The company is upgrading systems and believes it will be compliant, but failure of internal or third-party systems could have material adverse effects.
Investor Verification Checklist
- FDA Status: Verify the progress and preliminary results of the ORTHOVISC Phase III clinical trial initiated in April 1999.
- Customer Dependence: Monitor Bausch & Lomb's purchase volumes to ensure they continue to exceed minimum annual obligations under the supply agreement.
- Manufacturing Costs: Track the $1.6 million remaining capital expenditure for facility expansion and its impact on gross margins.
- Cash Burn vs. Revenue: Assess whether the $2.5 million clinical trial cost and operating expenses will be covered by current cash reserves without dilutive financing.
- Stock Repurchase Impact: Review the remaining authorization under the $4 million stock repurchase plan and its effect on share count and liquidity.